ChromaDex sees FY25 revenue up 18%
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 04 2025
0mins
Revenue Growth Projection: The company anticipates an 18% year-over-year revenue growth for 2025, driven by e-commerce expansion, partnerships, and increased sales from the Niagen ingredient business.
Expense Management and Investment: While selling and marketing expenses will rise in absolute terms, they will remain stable as a percentage of net sales; general and administrative expenses are expected to increase due to growth investments and the absence of a prior royalty expense reversal.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
